Biogen Inc. (BIIB) reported $2.46 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 0.4%. EPS of $5.28 for the same period compares to $4.02 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.38 billion, representing a surprise of +3.54%. The company delivered an EPS surprise of +32.00%, with the consensus EPS estimate being $4.00.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this company would post earnings of $3.45 per share when it actually produced earnings of $3.67, delivering a surprise of 6.38%.Over the last four quarters, the company has surpass ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-----------------------------------------------------------|-------|----------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Second Quarter 2024 Financial Results and Business Update | | | | | | | | | | | | | | | | | | | | August 1, 2024 | | Non-GAAP financial information This presentation and the discussions during this conference call include certain finan ...

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products beat expectations. Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share.The bio ...

Press Release Cambridge, Mass. – Aug. 1, 2024 Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 Second quarter total revenue was flat at actual currency and up 1% at constant currency, with GAAP diluted EPS decline of 2% and Non-GAAP diluted EPS increase of 31% year-over-year • Core pharmaceutical revenue (product revenue + LEQEMBI) up 5% at actual curr ...

Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PIERRE trial has been completed. 10 spinal muscular atrophy (SMA) patients have undergone ThecaFlex implantation and have received nusinersen through the device. No device-related adverse events, including infections, were observed in the 30 days after implantation. FDA has agreed to an additional 80-SMA patient ...

Industry Overview - The second-quarter 2024 reporting cycle for the Medical sector, which includes pharma/biotech and medical device companies, is gaining traction with several key companies reporting strong results [1] - As of July 24, 16.9% of companies in the Medical sector, representing 33.8% of the sector's market capitalization, reported quarterly earnings, with 100% outperforming both earnings and revenue estimates [1] - Year-over-year earnings for the Medical sector are expected to increase by 19.4%, while sales are projected to grow by 7.3% [1] Company Performance GSK plc - GSK has a solid track record, surpassing estimates in three of the last four quarters, with an average earnings surprise of 10.11% [3] - The Zacks Consensus Estimate for GSK's earnings per share is $1, driven by higher sales of newer products, which are expected to offset declines in older drug sales [4] Vertex Pharmaceuticals - Vertex has consistently beaten earnings estimates in the last four quarters, with an average surprise of 5.92% [5] - The Zacks Consensus Estimate for Vertex's revenues is $2.65 billion, with earnings estimated at $4.04 per share, driven by strong sales of its cystic fibrosis drug, Trikafta/Kaftrio [5] Biogen - Biogen has beaten earnings estimates in three of the last four quarters, with an average surprise of 3.91% [6] - The Zacks Consensus Estimate for Biogen's revenues is $2.38 billion, with earnings pegged at $4.00 per share, although sales are likely to be impacted by lower sales of multiple sclerosis drugs [7] Moderna - Moderna has exceeded earnings estimates in each of the last four quarters, with an average surprise of 55.39% [8] - The Zacks Consensus Estimate for Moderna's sales is $124.9 million, with an expected loss of $3.47 per share, as COVID-19 vaccine sales are anticipated to be minimal [8] Regeneron Pharmaceuticals - Regeneron has beaten earnings estimates in three of the last four quarters, with an average surprise of 4.47% [9] - The Zacks Consensus Estimate for Regeneron's revenues is $3.38 billion, with earnings estimated at $10.55 per share, driven by strong sales of the asthma drug Dupixent [9]

Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $4 per share in its upcoming release, pointing to a year-over-year decline of 0.5%. It is anticipated that revenues will amount to $2.38 billion, exhibiting a decline of 3.1% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimat ...

The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools have the potential to be used to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer’s disease CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July 30, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identif ...

Core Insights - Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to develop blood-based biomarkers for tau pathology in Alzheimer's disease, aiming to enhance patient stratification and treatment monitoring [1][2][3] Company Summaries Biogen - Founded in 1978, Biogen is a leading biotechnology company focused on innovative science to deliver new medicines and create value for shareholders and communities [4] - The company will provide Alzheimer's clinical study data and expertise in biomarker research to prioritize markers for tau pathology in the collaboration [3] Beckman Coulter - Beckman Coulter has over 80 years of experience in advanced diagnostics, aiming to improve patient health through innovative diagnostic solutions [5][6] - The company will be responsible for diagnostic development, manufacturing, and commercialization in the collaboration [3] Fujirebio - Fujirebio, part of H.U. Group Holdings Inc., has over 50 years of experience in in vitro diagnostics and aims to develop novel neurodegenerative disease diagnostics [7] - The company will collaborate to accelerate the development of blood-based biomarkers for tau pathology and deliver them globally [3]